Patterns of treatment and outcomes of patients with metastatic HER2-low breast cancer treated with CDK4/6 inhibitors and hormone therapy
CDK4/6i are effective in both HER2-low and HER2-0 MBC, with HER2-low potentially benefiting more from first-line therapy.
Authors
- Alberto Malovini (ORCID: https://orcid.org/0000-0003-2857-5773)
- Laura D. Locati (ORCID: https://orcid.org/0000-0003-3315-2580)
- Lorenzo Perrone (ORCID: https://orcid.org/0000-0001-5273-9788)
- Angioletta Lasagna (ORCID: https://orcid.org/0000-0002-9611-1164)
- Gavino Chessa
- Paolo Pedrazzoli (ORCID: https://orcid.org/0000-0002-9419-7160)
- Valentina Tibollo (ORCID: https://orcid.org/0000-0003-2687-3822)
- Barbara Tagliaferri (ORCID: https://orcid.org/0000-0002-4889-5574)
- Federico Sottotetti (ORCID: https://orcid.org/0000-0002-9679-6538)
- R. Palumbo (ORCID: https://orcid.org/0000-0002-0118-0563)
- C. Raso
- Gianpiero Rizzo
Institutions
- University of Pavia (IT)
- Istituti Clinici Scientifici Maugeri (IT)
- Policlinico San Matteo Fondazione (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
Publication Details
- Journal
- Drugs in Context
- Published
- 2025-05-03
- DOI
- https://doi.org/10.7573/dic.2024-12-1
- Citations
- 2
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 3.04